Ismail Anis, Hayek Salim S
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, 1500 E Medical Center Dr, CVC #2709, Ann Arbor, 48109, MI, USA.
Curr Cardiol Rep. 2023 Dec;25(12):1797-1810. doi: 10.1007/s11886-023-01991-7. Epub 2023 Nov 10.
Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR's role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target.
Clinical, genetic, and experimental evidence supports suPAR's role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.
慢性炎症是心血管疾病（CVD）风险的主要促成因素。可溶性尿激酶型纤溶酶原激活物受体（suPAR）是一种免疫衍生的糖蛋白，与动脉粥样硬化疾病密切相关。本综述总结了关于suPAR在CVD发病机制中的作用及其作为预后指标和治疗靶点的潜力的证据。
临床、遗传和实验证据支持suPAR作为动脉粥样硬化致病因素的作用。suPAR通过调节单核细胞的激活和功能促进动脉粥样硬化。在临床上，suPAR水平升高与不同人群的心血管风险增加有关。正在进行的临床试验正在评估针对suPAR信号传导的疗法。目前的证据表明，suPAR是骨髓细胞功能的调节剂，可导致血管炎症和随后的心血管事件。需要进一步的研究来确定测量suPAR是否可以改善CVD风险预测并实现个性化管理。总体而言，suPAR是一种有前景的免疫衍生生物标志物，也是减少炎症和心血管风险的靶点。
